● Recruiting

Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

Condition: Ovarian Cancer · Ovarian Cancer Metastatic Recurrent · Sponsor: Tel-Aviv Sourasky Medical Center

PhasePhase 2

Planned participants60

Who can joinFemale, 20 Years to 85 Years

Healthy volunteersNo

About this study

This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.

This description comes directly from the study's public registry record.

Talk to the study team

Shamgar Ben-Eliyahu, Prof. · 972-3-6407266 · shamgar@tauex.tau.ac.il

Always discuss trial participation with your own doctor first.

Locations (2)

The Chaim Sheba Medical Center	Ramat Gan, Israel	Recruiting
Tel Aviv Sourasky Medical Center (Ichilov Hospital)	Tel Aviv, Israel	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06839144